Breaking News

Ardea Earns Bayer Milestone

Initiates second phase of Phase I/II study

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Ardea Biosciences has earned a $7.5 million milestone from Bayer HealthCare under an April 2009 license agreement to develop and commercialize Ardea’s mitogen-activated ERK kinase (MEK) inhibitor compounds for cancer and other indications.   The milestone was triggered by the initiation of the second phase of a previously reported Phase I/II study evaluating BAY 86-9766 in combination with gemcitabine for the treatment of advanced pancreatic cancer....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters